Effective co-administration of infliximab and etanercept following the failure of sequential anti-TNF agents in a patient with HLA-B27-associated arthropathy [6]

Rheumatology

Volumn 45, Issue 10, 2006, Pages 1314-1315

  Sheehy, C ^a   Murphy, E ^a   Barry, M ^a  

^a Royal College of Surgeons in Ireland   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AUROTHIOMALATE; COTRIMOXAZOLE; DOXYCYCLINE; ETANERCEPT; HLA B27 ANTIGEN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE;

ADULT; ANAMNESIS; CASE REPORT; CLINICAL FEATURE; DISEASE DURATION; DRUG DOSE REGIMEN; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; KNEE ARTHRITIS; LETTER; MALE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SYNOVECTOMY; SYNOVITIS; TREATMENT FAILURE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DRUG THERAPY, COMBINATION; HLA-B27 ANTIGEN; HUMANS; IMMUNOGLOBULIN G; JOINT DISEASES; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33749647736     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel211     Document Type: Letter

References (10)

1. Nikas SN, Temekonidis TI, Zikou AK, Argyropoulou MI, Efremidis S, Drosos AA. Treatment of resistant rheumatoid arthritis by intra-articular infliximab injections: A pilot study. Ann Rheum Dis 2004;63:102-3.
2. Scallon B, Cai A, Solowski N et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301:418-26.
3. Mpofu S, Fatima F, Moots RJ. Anti-TNF-alpha therapies: They are all the same (aren't they?). Rheumatology 2005; 44:271-3.
4. Catrina AI, af Klint E, Ernestam S et al. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum 2006;54:76-81.
5. Zwerina J, Hayer S, Tohidast-Akrad M et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: Effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004;50:277-90.
6. van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003;62:1195-8.
7. Cohen G, Courvoisier N, Cohen JD, Zaltni S, Sany J, Combe B. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005;23:795-800.
8. Padyukov L, Lampa J, Heimburger M et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003;62:526-9.
9. Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum 2005; 52:2693-6.
10. Tai TL, O'Rourke KP, McWeeney M, Burke CM, Sheehan K, Barry M. Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology 2002;41:951-2.